Belite Bio
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
12750 High Bluff Dr Ste 475, San Diego, ...Phone Number
(858) 246-6240Website
www.belitebio.comRevenue
-Stock Symbol
BLTEIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
2
About Belite Bio
Belite Bio is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. They are based in San Diego, California.Explore more
Belite Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Belite Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Belite Bio has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Belite Bio has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Belite Bio recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Belite Bio
Click to see if Belite Bio had a recent Job posting/layoffs
Check out if Belite Bio is spiking on competitors!
Product Launch: Get notified when Belite Bio launches new products
Belite Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Belite Bio
Find 2 more new buyers
Compare Similar Companies to Belite Bio
Compare insights from companies similar to Belite Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Belite Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Belite Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Belite Bio.
Belite Bio Tech Stack
A closer look at the technologies used by Belite Bio
Most Recent Scoops
Project
Belite Bio has reported that the primary adverse events observed with Tinlarebant across clinical trials are xanthopsia and delayed dark adaptation, both predominantly mild in severity and manageable through patient education, with no serious ocular Treatment-Emergent Adverse Events (TEAEs) recorded and only four TEAEs leading to study drug discontinuation.
Clinical Operations
Project
Belite Bio has reported that the pivotal DRAGON trial demonstrated a 37% reduction in the growth rate of definitely decreased autofluorescence (DDAF) lesions in Stargardt disease patients treated with Tinlarebant, with supporting structure-function correlation data between DDAF and visual acuity loss presented independently by Stanford University at the ARVO meeting in May.
Medical Research, Pharmaceuticals, Clinical Operations
Project
demonstrated in preclinical studies using mouse models that reducing RBP4 by 80% with the equivalent dose of 5 milligrams per day Tinlarebant can completely stop photoreceptor degeneration in a double knockout mouse model (RDH8 plus ABCA4), essentially rescuing the Stargardt disease model.
Medical Research, Pharmaceuticals
Project
reported that Tinlarebant's treatment emergent adverse events were primarily ophthalmic and aligned with its mechanism of action, including delayed dark and light adaptation (5 to 10 minutes longer to reach final threshold in darkness) and visual scene discoloration. Approximately one-third of patients experienced xanthopsia or dyschromatopsia lasting seconds or minutes, and another third noticed longer dark adaptation times, with almost all events rated as mild and many resolving over time.
Pharmaceuticals, Clinical Operations
Product Launch
Product Development, Medical Research, Pharmaceuticals
Belite Bio News & Media
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the New Drug Application (NDA) for tinlarebant for the treatment of Stargardt Disease Type 1 (STGD1). ThBelite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Thursday, August 13, 2026, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the second quarter ended June 30, 2026.Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced additional, positive secondary endpoint data from its Phase 3 DRAGON trial of tinlarebant in Stargardt disease type 1 (STGD1). The findings, along with previously reported topline data, were delivered in an orBelite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a panel discussion at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026, at 3:00 pm ET.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Belite Bio
Sign Up For FreeTo access detailed company insights
Belite Bio is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. They are based in San Diego, California.... Read More
